Sabra Health Care price target raised to $22 from $21 at BofA

BofA raised the firm’s price target on Sabra Health Care (SBRA) to $22 from $21 and keeps a Buy rating on the shares. A “silver tsunami’ in the U.S. is expected to to drive big gains for the major players in the senior housing business as Boomers age into senior living, says the analyst, who forecasts that margins for the five SHOP REITs- Welltower (WELL), Ventas (VTR), Sabra, American Healthcare REIT (AHR) and National Health Investor (NHI) – will expand ahead of Street estimates in 2026.